Eurand NV, a global specialty pharmaceutical company, announced the grant of US Patent No. 7,658,918, titled "Stable Digestive Enzyme Compositions," by the United States Patent and Trademark Office (US PTO). The patent will provide Eurand with coverage until at least February 20, 2028 on Zenpep (pancrelipase) Delayed-Release Capsules.

In 2009, the US Food and Drug Administration (FDA) granted ZENPEP five years of marketing exclusivity as a New Chemical Entity.

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies.